in silico methods in fragment-based drug design — a Protein Kinase B case study

webinar

Wed, 28 Jan 2015, 19:00 CET (Berlin)

Dr. Alastair Donald, BioSolveIT GmbH, St. Augustin, Germany

in silico methods in fragment-based drug design — a Protein Kinase B case study

Computational tools are invaluable in the process of identifying high-quality fragment hits. In this one hour BioSolveIT webinar you will learn how to fast-track your fragment hit discovery using our cutting edge in silico solutions using Protein Kinase B as an example.

By the end you will appreciate how our suite of SBDD tools can enrich your work life, enhance your productivity and assist in the identification of potent, selective and synthetically accessible lead-like molecules.

So, if you are interested in

  • enriching your screening collection with potent and selective fragments
  • intelligently selecting which commercially available analogs to purchase
  • deciding which analogs to prioritize for synthesis
  • saving time and money by focusing on the most promising ideas

watch the video live recording below.

Current news

category
Events
Announcing BioSolveIT's DrugSpace Symposium 2025: Bridging Science
June 26, 2025 09:43 CEST
We are pleased to announce the fourth edition of the BioSolveIT DrugSpace Symposium, taking place on September 24–25, 2025. This year’s theme, “Bridging Science,” highlights the growing importance of interdisciplinary collaboration in driving innovation across the drug discovery landscape. As the field evolves, it becomes increasingly clear that real progress...
Read on
Psst... Are You Following Us Yet? Follow the Science (and a Bit More)
June 25, 2025 08:44 CEST
There’s a lot going on behind the scenes—ideas taking shape, tools evolving, science in motion. And while the website tells you what our software does, our social media gives you a look at how it lives. We’re active on LinkedIn, BlueSky, and YouTube, sharing everything from scientific snapshots to educational...
Read on
AMBrosia Just Got Bigger: 126 Billion Compound Update Now Available
June 11, 2025 13:21 CEST
We are thrilled to announce a major update to the AMBrosia Chemical Space in collaboration with Ambinter! The state-of-the-art source for diverse drug-like scaffolds now boasts an incredible 126 billion of synthetically accessible compounds for drug discovery projects. What does the update feature? Expanded to an astounding 125,924,571,692 compounds (1.26...
Read on